GUANABENZ ( DrugBank: Guanabenz )

---

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
2	筋萎縮性側索硬化症	1
13	多発性硬化症／視神経脊髄炎	1

2. 筋萎縮性側索硬化症

---

臨床試験数 : 645 /  薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2014-005367-32-IT (EUCTR)	29/02/2016	17/03/2017	Clinical study on the efficacy and tolerabilty of Guabenz in Amiotropic Lateral Sclerosis	PROTEIN MISFOLDING, AMYOTROPHIC LATERAL SCLEROSIS AND GUANABENZ: A PHASE II RCT WITH FUTILITY DESIGN - PROMISE	Amiotrophic Lateral Sclerosis MedDRA version: 19.1;Level: PT;Classification code 10028003;Term: Motor neurone disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: GUANABENZ ACETATO Product Code: GUANA2015 INN or Proposed INN: GUANABENZ Other descriptive name: GUANABENZ Product Name: RILUZOLO INN or Proposed INN: RILUZOLO Other descriptive name: RILUZOLO	FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	208	Phase 2	Italy

13. 多発性硬化症／視神経脊髄炎

---

臨床試験数 : 3,340 /  薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02423083 (ClinicalTrials.gov)	April 21, 2015	21/4/2015	Oral Guanabenz for Multiple Sclerosis	Phase I Study of Oral Guanabenz for Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis	Drug: Guanabenz	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Terminated	18 Years	55 Years	All	2	Phase 1	United States